Citius Pharmaceuticals, Inc. CTXR

Citius Oncology released fiscal third quarter 2026 financial results and a business update. Quarterly results and business updates can moderately shift near-term investor views and trading for CTXR.

Citius Oncology reports strong commercial momentum for its cancer treatment. Strong commercial momentum for cancer treatment signals major revenue growth and competitive gains for Citius Pharmaceuticals.

Citius Oncology deployed LYMPHIR's broadened commercial organization nationwide with expanding market adoption. Nationwide LYMPHIR rollout and adoption directly boosts revenue potential and market position for CTXR.

Citius Oncology will present LYMPHIR® Phase 1 combination study data at the 2026 ASCO Annual Meeting. Phase 1 data presentation at ASCO raises pipeline visibility and may lift near-term sentiment for CTXR.

Citius Oncology, Inc. reported fiscal second quarter 2026 financial results and provided a business update. Quarterly financial results and business updates supply performance data that can shift near-term investor sentiment for the company.

Citius Pharmaceuticals reported fiscal second quarter 2026 financial results and provided a business update. Quarterly results and updates supply performance metrics and pipeline status that moderately shape near-term investor views.

Citius Oncology, a subsidiary of Citius Pharmaceuticals (CTXR), shipped the first international order of its FDA-approved immunotherapy LYMPHIR™ to a distributor in Europe. First international shipment of LYMPHIR expands market access to Europe, enhancing revenue streams and global presence.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) may achieve profitability soon. Potential profitability signals a major financial milestone that could significantly boost CTXR's market performance and investor confidence.

Citius Oncology reports strong early adoption of LYMPHIR™ following launch, with expanding clinical development initiatives underway. Commercial update on key oncology drug launch demonstrates early market traction and pipeline growth, significantly impacting revenue and investor sentiment.

Citius Oncology announced positive topline results from an investigator-initiated Phase 1 study of LYMPHIR™ combined with pembrolizumab in patients with relapsed or refractory gynecologic cancers. Positive Phase 1 topline data expands LYMPHIR's potential in a new oncology indication, providing moderate pipeline validation for CTXR.

Citius Pharmaceuticals, Inc. (CTXR) commercially launches LYMPHIR, becoming a revenue-generating company. Commercial launch of LYMPHIR initiates revenue for CTXR, significantly enhancing financial prospects and market trajectory.

Citius Oncology released preliminary topline Phase 1 data on LYMPHIR dosing before commercial CAR-T therapy in high-risk diffuse large B-cell lymphoma. Positive Phase 1 results expand LYMPHIR application in lymphoma and strengthen Citius pipeline prospects.

Citius Pharmaceuticals, Inc. reported its first revenue following the successful launch of LYMPHIR™, a treatment for patients with certain types of cancer. The company highlighted the positive reception of the product in the market and its potential to drive future growth. This marks a significant milestone for Citius as it transitions into a revenue-generating phase. The successful launch of LYMPHIR™ is expected to significantly impact Citius Pharmaceuticals' future performance and market position.

Citius Oncology, Inc. has reported its first revenue following the successful launch of LYMPHIR™, a treatment for patients with certain types of cancer. This marks a significant milestone for the company as it begins to generate income from its innovative product, which is expected to enhance its market position and financial performance. The successful launch of LYMPHIR™ and the generation of revenue are likely to significantly impact the company's future performance and investor sentiment.

Citius Pharmaceuticals, Inc. has entered into a European distribution agreement with Uniphar for its product Lymphir, which is aimed at treating cancer. This partnership is expected to enhance the availability of Lymphir in European markets, potentially expanding the company's reach and impact in oncology. The distribution deal is a significant strategic move that could enhance market presence and investor sentiment.

Citius Pharmaceuticals, Inc. has expanded the international distribution of its product LYMPHIR™ to the European Union through an exclusive agreement with Uniphar. This partnership aims to enhance the availability of LYMPHIR™ in European markets, potentially increasing the company's reach and sales in the region. The exclusive agreement with Uniphar represents a significant strategic move that could enhance market presence and revenue potential in Europe.

Citius Oncology, Inc. reported its financial results for fiscal year 2025, highlighting key metrics and providing a business update. The company outlined its strategic initiatives and progress in product development, emphasizing its commitment to advancing oncology treatments. Financial performance indicators showed growth, and management expressed optimism about future prospects and ongoing projects. Financial results and strategic updates indicate moderate influence on the company's future performance and market positioning.

Citius Pharmaceuticals, Inc. reported its financial results for fiscal year 2025, highlighting key metrics and providing a business update. The company outlined its strategic initiatives and progress in product development, emphasizing its commitment to advancing its pipeline and enhancing shareholder value. The financial results and business update indicate moderate influence on the company's future performance and market positioning.

Citius Pharmaceuticals, Inc. (CTXR) has successfully closed an $18 million concurrent registered direct offering and private placement, priced at-the-market under Nasdaq rules. The financing is expected to enhance the company's financial position and support its ongoing development initiatives. The funding will provide necessary capital for development, impacting financial performance and operational capabilities.

Citius Pharmaceuticals, Inc. (CTXR) has announced an $18 million concurrent registered direct offering and private placement, priced at-the-market under Nasdaq rules. The financing aims to support the company's ongoing clinical development and operational initiatives. This move is expected to enhance liquidity and provide necessary capital for advancing its oncology programs. The $18 million capital raise is a significant strategic move that could enhance the company's ability to fund critical development projects and improve investor sentiment.

Citius Pharmaceuticals, Inc. has expanded the distribution of its LYMPHIR™ product to Turkey and several Middle Eastern countries through an exclusive agreement with Er-Kim. This strategic partnership aims to enhance the availability of LYMPHIR™, which is designed for treating patients with certain types of cancer, thereby increasing the company's market reach and potential revenue in these regions. The exclusive distribution agreement significantly expands market access for LYMPHIR™, likely impacting future revenue and investor sentiment.

Citius Pharmaceuticals, Inc. has announced the U.S. commercial launch of LYMPHIR™, a novel immunotherapy specifically designed for the treatment of Cutaneous T-Cell Lymphoma (CTCL). This innovative therapy aims to provide a new treatment option for patients suffering from this rare form of cancer, potentially improving outcomes and quality of life. The launch of LYMPHIR™ represents a significant strategic move that could enhance Citius Pharmaceuticals' market position and investor sentiment.

Citius Oncology will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting, showcasing its innovative therapies and research in hematology. The event is a significant platform for the company to engage with key stakeholders and present its advancements in oncology treatments, potentially enhancing its visibility and collaboration opportunities within the industry. Participation in a major industry event can moderately influence Citius Pharmaceuticals' visibility and networking opportunities, impacting its competitive positioning.

Citius Pharmaceuticals, Inc. is advancing the commercial launch of its LYMPHIR™ product by integrating Verix AI technology. This collaboration aims to enhance the efficiency and effectiveness of LYMPHIR™ in oncology treatments, potentially improving patient outcomes and streamlining operations. The integration of Verix AI with LYMPHIR™ represents a significant strategic move that could enhance product performance and market positioning.

Citius Pharmaceuticals, Inc. (CTXR) is projected to reach breakeven in the near future, indicating potential improvements in financial performance and operational efficiency. The company's strategic initiatives and product developments are expected to contribute positively to its market position and investor confidence. The expectation of breakeven suggests significant improvements in financial health and operational strategy.

Citius Pharmaceuticals, Inc. has successfully closed a registered direct offering, raising $6.0 million priced at-the-market under Nasdaq rules. The offering is expected to enhance the company's financial position and support its ongoing development initiatives. The capital raised may moderately influence Citius Pharmaceuticals' financial performance and development efforts.

Citius Pharmaceuticals, Inc. announced a registered direct offering of $6.0 million priced at-the-market under Nasdaq rules. The offering is expected to enhance the company's financial position and support its ongoing development initiatives. The transaction is anticipated to close on or about October 30, 2023. The offering may provide necessary funding for development but is not expected to significantly alter the company's overall trajectory.

Citius Pharmaceuticals, Inc. has entered into a U.S. distribution agreement with McKesson to facilitate the commercial launch of LYMPHIR™, its innovative treatment for patients with certain types of cancer. This partnership aims to enhance the availability and distribution of LYMPHIR™, marking a significant step in Citius's efforts to bring this therapy to market and improve patient access. The distribution agreement with McKesson is a major strategic move that could significantly enhance market access and investor sentiment for Citius Pharmaceuticals.

Citius Pharmaceuticals, Inc. and its subsidiary Citius Oncology are set to participate in several conferences scheduled for October 2025. These events are expected to provide a platform for the companies to showcase their advancements and engage with stakeholders in the pharmaceutical and oncology sectors. Participation in upcoming conferences may enhance visibility and networking opportunities, potentially influencing market sentiment.

Citius Pharmaceuticals, Inc. has entered into an exclusive commercialization agreement with EVERSANA to support the planned launch of LYMPHIR™ in Q4 2025. This partnership aims to enhance the market introduction and distribution of the product, which is expected to play a significant role in Citius's future operations. The exclusive commercialization agreement with EVERSANA is a significant strategic move that could greatly influence Citius's market performance and investor sentiment.